Home  |  About  |  PCSK9  |  News  |  Commentary  |  Trials  |  Videos  |  Resources  |  Contact PCSK9 FORUM will be reporting live from the 66th Annual Scientific Session of the American College of Cardiology, March 17-19, Washington DC All eyes will be focused on FOURIER, the first cardiovascular outcomes trial with a PCSK9 inhibitor (evolocumab) added to background statin therapy. As PCSK9 Forum Editor Professor Anthony Wierzbicki discusses, how will this add to evidence from past IVUS and clinical studies? Check back to see expert analysis of FOURIER at ACC. ACC 2017 will also address other important questions about PCSK9 inhibition Are the PCSK9 inhibitors safe in the long-term? Check back for data from the ODYSSEY programme, FOURIER and the SPIRE trials Is there a link between PCSK9 inhibition and neurocognitive effects? Check back for analysis of EBBINGHAUS and REGARDS What can we learn from the SPIRE programme? Safety and cardiovascular event efficacy with bococizumab Can a single injection treatment provide long-term PCSK9 inhibition? Check back for answers from the ORION-1 trial with inclisiran The PCSK9 Forum Editorial Board will provide expert analysis of all the highlights from ACC. Join us here: 17-19 March 2017 Our popular therapeutic guide Third edition coming soon updated with the latest information discussing the biology and therapeutic potential of PCSK9 inhibition. Read online » Download now » Forward to colleagues »   Questions & Answers Read the full answer and other questions on the PCSK9 Forum » Like us on Facebook For the latest updates, PCSK9 news and analysis. Follow us on Twitter Hot topics, news and conference reports. YouTube Channel For videos, interviews and webcasts from leading experts. Educational Partners and Supporters Copyright PCSK9 Forum 2017. Please click here to unsubscribe from future mailings.